+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 20 Actively Recruiting clinical trials

N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
R

Actively Recruiting

This study aims to collect prospective safety and effectiveness data for the C-Brace System, a microprocessor-controlled knee ankle foot orthosis, following standard care practices. The research focuses on patients with lower extremity pareses who are fitted with the C-Brace device. The goal is to better understand how the C-Brace influences walking speed, balance, risk of falling, and confidence in balance over time. The C-Brace is a custom-made device with thigh, calf, and foot components connected by an ankle joint or spring element. It uses sensors to continuously monitor knee joint movement and walking phases, adjusting hydraulic resistance and knee motion accordingly. Patients enrolled in the registry will undergo baseline evaluation, fitting, training or therapy sessions, and follow-up visits at 6, 12, 24, and 36 months after fitting. Participants will be assessed through various tests including timed walk tests, balance confidence scores, and mobility assessments at different intervals. The study also tracks falls related to device use and changes in activity levels with an activity tracker. Data collected will help characterize the safety and functional impact of the C-Brace over three years of follow-up.

All AgesAll Genders
76 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
R

Actively Recruiting

Researchers are evaluating treatments for amblyopia in children aged 4 to 7 years. The study compares watching dichoptic movies or shows using the Luminopia virtual reality headset for 1 hour a day, 6 days a week, against patching the fellow eye for 2 hours a day, 7 days a week. The goal is to see if the dichoptic treatment is not worse than patching in improving distance visual acuity in the amblyopic eye over 26 weeks. Participants are randomly assigned to one of two groups the Luminopia group, who watch dichoptic content through a headset daily, or the patching group, who wear an eye patch for specified times. After 26 weeks, if participants in the patching group do not show sufficient improvement, they are offered the Luminopia therapy with follow-up visits at weeks 39 and 52. Those who do not qualify for this extension end the study after 26 weeks. During the study, participants undergo clinical assessments at 13 and 26 weeks post-randomization to measure changes in vision. Follow-up visits are scheduled for participants who switch to Luminopia after patching if needed. Researchers monitor adherence to treatment, visual acuity changes, and any safety concerns throughout the trial, which lasts up to 52 weeks for some participants.

Age: 4Years - 7YearsAll GendersPhase 3
73 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
S

Actively Recruiting

Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.

Age: 18Years +All Genders
849 locations
R

Actively Recruiting

Researchers are comparing durvalumab immunotherapy to the usual post-surgery observation approach for people with early-stage non-small cell lung cancer who have no remaining cancer cells after standard treatment. This phase III trial focuses on patients with stage II to IIIB disease who achieved a complete response following neoadjuvant chemo-immunotherapy. The study aims to find out whether durvalumab can help patients live longer and prevent cancer from coming back compared to just monitoring after surgery. Participants are randomly assigned to one of two groups. One group receives durvalumab intravenously once every 28 days for up to 12 cycles, provided there is no disease progression or unacceptable side effects. The other group undergoes active surveillance without additional treatment for 12 months. During the trial, all participants have regular CT scans and blood samples taken. After treatment or surveillance, patients are followed annually for up to 10 years. Throughout the study, participants complete questionnaires assessing quality of life and symptoms. Researchers monitor disease-free survival, overall survival, and adverse events up to 10 years after randomization. The trial also collects specimens and images for future research. Participants have regular visits for scans, blood tests, and assessments to evaluate the safety and effects of durvalumab compared to observation.

Age: 18Years +All GendersPhase 3
284 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations

1-10 of 20

1